Recent work by Zhivaki et al. shows that hyperactive cDC1s produce mature IL-1β in a NLRP3-dependent, but pyroptosis-independent manner and display an enhanced ability to take up and present TAAs, migrate to tumor-draining LNs and promote antitumor effector CD8+ T cells, altogether establishing a durable antitumor response. The gene discussed is CD8A; the disease is neoplasm.